At a glance
ClinicalIndex Comparison RecordPhase 2Terminated· 120 enrolled
Drug / intervention
KN046 +5 moredrug
Likely dose
KN046 3mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of KN046 in Patients With Advanced Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating KN046, Carboplatin, and 2 other interventions for Stage IV Non-small Cell Lung Cancer. Terminated early, enrolled 120 participants across 1 site.
Signals
Trial was terminated early
Detailed Summary
This is a phase II, open label, multicenter study in subjects with advanced non-small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage IV Non-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2TerminatedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartMay 2019
Primary CompletionJul 2022
TodayJul 2026
First PostedFeb 12, 2019
Enrollment StartMay 5, 2019
Primary CompletionJul 30, 2022
TodayJul 1, 2026
Enrollment to primary: 3.2 yearsPosted 7.4 years ago
Interventions
KN046drug
3mg/kg, Q2W, intravenous injection (IV)
KN046drug
5mg/kg, Q2W, intravenous injection (IV)
KN046drug
5mg/kg, Q3W, intravenous injection (IV)
Carboplatindrug
AUC 5 IV Q3W; total dose calculated according to the Calvert formula, with the highest dose not exceeding 750 mg; 4 cycles.
Pemetrexeddrug
500 mg/m2, Q3W, intravenous injection (IV)
Ningetinibdrug
Oral, QD